Rx Propellant, a leading life sciences infrastructure platform backed by Actis, has launched 1GV, a 136,000 sq. ft. research and innovation campus spanning 1.8 acres in Genome Valley, Hyderabad. This milestone reinforces the company’s commitment to advancing India's life sciences sector.

1GV is deeply connected to Genome Valley’s origins, built on the historic site where the region’s first infrastructure was established. Over the years, this location has played a crucial role in India’s pharmaceutical, biotech, and contract research advancements. By developing 1GV, Rx Propellant continues this legacy, fostering innovation and scientific progress.

Designed with sustainability in mind, 1GV boasts LEED Platinum & IFC EDGE Advanced Pre-Certification, reflecting environmentally responsible development. The campus features state-of-the-art, scalable, and adaptable facilities, creating an optimal environment for life sciences enterprises. Additionally, it includes collaborative spaces to enhance connectivity, productivity, and well-being.

With the addition of 1GV, Rx Propellant now operates three campuses, further solidifying its leadership in India’s life sciences infrastructure. CEO Milind Ravi highlighted that this expansion strengthens the company’s footprint in Genome Valley, a key biotech hub, and aligns with its vision of delivering sustainable, cutting-edge infrastructure across India.